Resilience subsidiary Ology Bioservices awarded up to $250M DOD contract for botulinum neurotoxin treatment

National Resilience, Inc. announced that its subsidiary Ology Bioservices was awarded a contract valued up to $250 million from the U.S. Department of Defense for manufacturing development of a monoclonal antibody against botulinum neurotoxin.

“We are proud to support the Department of Defense develop this important medicine to protect the warfighter from exposure to botulinum toxins.”biospace.com

• 1 source
• biospace.comResilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin TreatmentGabrielle MassonFeb 9, 2022

Summarized from public sources; check the original articles before acting on it.